Editas medicine stock price.

All three healthcare stocks are showing solid long-term potential. ... Editas Medicine is focusing on a gene therapy EDIT-301 for rare blood disorders. ... Price as of November 30, 2023, 4:00 p.m ...Nov 30, 2023 · A high-level overview of Editas Medicine, Inc. (EDIT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. On June 15, Editas Medicine ( EDIT 2.23%) saw its shares collapse by 15% after announcing it would be issuing new stock to raise approximately $125 million. The biotech will almost certainly use ...Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.What's Happening With Editas Medicine Inc Stock Today? Editas Medicine Inc (EDIT) stock is up 0.19% while the S&P 500 has fallen -0.91% as of 11:28 AM on …

Snap's stock is now far below its all-time high of close to $80 in 2021, but patient investors could see shares reach and exceed that price. Prosper Junior Bakiny has no position in any of the ...

Get Editas Medicine Inc (EDIT.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsEditas Medicine Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:55 p.m. EST Delayed quote $ 10.73 -0.04 -0.37% After Hours Volume: 26.03K Advanced Charting...

Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently up 51.5% so far this month. During the month of November, Editas Medicine Inc’s stock price has reached a high of $11.14 and a low of $6.66. Over the last year, Editas Medicine Inc has hit prices as high as $11.93 and as low as $6.08. Year to date, Editas ...Editas Medicine Inc’s Stock Price as of Market Close. As of March 13, 2023, 4:00 PM CST, Editas Medicine Inc’s stock price was $8.43. Editas Medicine Inc is up 7.66% from its previous closing price of $7.83. During the last market session, Editas Medicine Inc’s stock traded between $7.48 and $8.15. Currently, there are 68.79 million …Price as of November 24, 2023, 1:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.Research Editas Medicine's (Nasdaq:EDIT) stock key valuation metrics while comparing it with its industry peers & market side by side. ... The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$10 ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …

Editas Medicine Stock Forecast 11-26-2023. Forecast target price for 11-26-2023: $ 10.97. Positive dynamics for Editas Medicine shares will prevail with possible volatility of 3.528%. Pessimistic target level: 10.80. Optimistic target level: 11.19.

Future criteria checks 2/6. Editas Medicine is forecast to grow earnings and revenue by 0.04% and 51.7% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be -133.7% in 3 years.

Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine is a gene-editing technology company. Editas Medicine has lost over 60% of its value. Check out why I'm neutral on EDIT stock here.Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine Stock Forecast. ... According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts an ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...

Editas Medicine, Inc. Common Stock (EDIT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 24 Okt 2023 ... Stock Price Forecast. According to 12 stock analysts, the average 12-month stock price forecast for EDIT stock stock is $14.17, which predicts ...Moreover, the 36-month beta value for EDIT is 1.79. Analysts have varying opinions on the stock, with 6 analysts rating it as a “buy,” 2 as “overweight,” 8 as “hold,” and 1 as “sell.” The average price recommended by analysts for Editas Medicine Inc (EDIT) is $13.93, which is $5.41 above the current market price.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Editas Medicine Inc Stock Price History. Editas Medicine Inc’s price is currently down 3.99% so far this month. During the month of August, Editas Medicine Inc’s stock price has reached a high of $9.52 and a low of $8.39. Over the last year, Editas Medicine Inc has hit prices as high as $19.97 and as low as $6.33. Year to date, Editas ...Editas Medicine, Inc. ( EDIT) NASDAQ: EDIT · IEX Real-Time Price · USD Add to Watchlist Buy EDIT 10.58 +0.09 (0.86%) At close: Nov 24, 2023, 1:00 PM 10.53 …

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Get the latest Editas Medicine, Inc. (EDIT) stock news and headlines to help you in your trading and investing decisions.

Editas Medicine. Market Cap. $860M. Today's Change. (-0.75%) -$0.08. Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...Mar 27, 2023 · Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ... Price as of December 1, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street.The flu season can strike at any time, leaving us feeling unwell with symptoms like fever, cough, sore throat, and fatigue. While getting a flu shot is the best prevention, sometimes the flu sneaks through. That’s when having the right over...Editas Medicine stock quote and company news. Get the latest EDIT company stock news & quotes.Real time Editas Medicine (EDIT) stock price quote, stock graph, news & analysis.Stock price history for Editas Medicine (EDIT). Highest end of day price: $90.58 USD on 2021-01-08. Lowest end of day price: $6.36 USD on 2023-04-12. Stock ...Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics Motley Fool - Mon Oct 2, 9:00AM CDT . The better of the pair should be able to beat Bluebird Bio. EDIT: 10.77 (+2.28%) CRSP: 68.65 (+2.88%) Why Editas …

Find the latest Editas Medicine, Inc. (EDIT) stock quote, history, news and other vital information to help you with your stock trading and investing.

Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases.

Apr 6, 2023 · Editas Medicine (EDIT 0.86%) and Bluebird Bio (BLUE 2.64%) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ...Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Here are three top biotech stocks with major catalysts in December. Editas Medicine ( EDIT ): EDIT will release key clinical data on its sickle cell treatment on Dec. …Editas Medicine's cash burn of US$181m is about 36% of its US$503m market capitalisation. That's fairly notable cash burn, so if the company had to sell shares to cover the cost of another year's ...Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. Consider, for instance, Editas Medicine (EDIT-6.20%) ... Stock Advisor list price is $199 per year. Join Stock Advisor Cumulative Growth of a $10,000 Investment in Stock Advisor.With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Complete Editas Medicine Inc. stock information by Barron's. View real-time EDIT stock price and news, along with industry-best analysis.On average, Wall Street analysts predict. that Editas Medicine's share price could reach $14.00 by Oct 24, 2024. The average Editas Medicine stock price prediction forecasts a potential upside of 31.95% from the current EDIT share price of $10.61 .Find the latest Editas Medicine, Inc. (EDIT) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

The sale of Editas stock could be related to the biotech's upcoming announcement of clinical data. ... Price as of November 29, 2023, 4:00 p.m. ET ... Keith Speights owns shares of Editas Medicine ...Jan 26, 2023 · Current Price. $10.46. Price as of November 22, 2023, 11:14 a.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ... Stock price history for Editas Medicine (EDIT). Highest end of day price: $90.58 USD on 2021-01-08. Lowest end of day price: $6.36 USD on 2023-04-12. Stock ...Instagram:https://instagram. jet blue pilot paymarkor international furniturewhen is the stock market going to go back upsotheby's auction calendar Current Price. $10.53. Price as of November 30, 2023, 4:00 p.m. ET. ... Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics. These 2 Stocks Could Skyrocket by 54% and 119% ...Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in ... great penny stock to buystock high Another Jennifer Doudna co-founded company is Editas Medicine (NASDAQ: EDIT). Like Intellia, Editas is among the gene editing stocks using CRISPR/Cas9 systems to to solve incurable diseases. is mt4 a broker The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it intends to offer and sell $125 million of shares of its common stock in an underwritten public offering. Editas Medicine intends to grant the underwriters a 30-day option to …